▶주메뉴 바로가기
▶본문 바로가기
South Korean biotech firm Bridge Biotherapeutics announced Oct. 25 that it had received preliminary screening approval for Kosdaq listing.The company applied for approval Sept. 3 and expects to be listed on the second-tier Kosdaq market in December this year.“We will continue to develop and ad...
The Ministry of Food and Drug Safety on Oct. 16 ordered Medytox to withdraw and dispose of the entire batch of its botulinum toxin Meditoxin produced for exports.The problematic products were produced on Oct 6, 10 and 19 of 2016 and its expiry date is Oct 5, 11 and 18 this year, respectively. The Ko...
Daewoong Pharmaceutical announced Oct. 16 it has launched its botulinum toxin under the name Nuceiva in Canada.It is the first South Korean company to enter the Canadian market with a botulinum toxin brand.“Like the US market, Canada also has only three types of botulinum toxins which have bee...
South Korea’s Supreme Court announced on Oct. 16 that it has approved a request by Samsung BioLogics to suspend the execution of penalties by the financial watchdog on Oct. 11.The court’s recent decision came after the lower courts approved the same request of Samsung BioLogics in Februa...
Daewoong Pharmaceutical on Oct. 7 denied allegations by Medytox that it stole manufacturing secrets, including its Hall A Hyper strain, to develop its botulinum toxin Nabota.“Medytox is saying that its Hall A Hyper strain, which was proven to not form spores by multiple professionals for decad...
South Korean drugmaker Daewoong Pharmaceutical said Oct, 2 it has won approval from European authorities for the sale of its botulinum toxin product. The European Commission accepted Daewoong’s application to sell Nabota, Korea’s first botulinum toxin product to receive the green light ...
Samsung BioLogics has won a lawsuit against Switzerland-based Lonza to nullify its patents involving its cell line development technology in South Korea, according to sources Oct. 1.The court noted Lonza’s patented technology is not new compared to the one that is being widely used and it is a...
South Korean biotech firm Genexine announced on Sept. 27 that it has signed a contract with the Thai company KinGen Holdings to establish a 50:50 joint venture named KinGen Biotech.KinGen Holdings is a Thai consortium that is backed by the government, schools and divers investors, according to Genex...
Celltrion Healthcare on Sept. 27 announced its decision to expand sales in the Middle East.He company has got approval to exclusively supply Remsima, its version of Johnson & Johnson’s Remicade from the third quarter this year. According to the company, its successful bid was due to its ag...
Celltrion Group on Sept. 20 announced that European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended giving sales approval for Remsima SC.CHMP is responsible for preparing the opinions to EMA on questions concerning human medicines based on scientific evidence....
Medytox has participated in the seed-funding round of US startup LifeSprout, according to industry sources on Sept. 16.Although the Korean company declined to confirm the specific amount that it has funded, a local news outlet reported that it invested around $1.5 million in this round.The US compan...
Korean pharmaceutical companies are making inroads into the Central and South American markets, betting on their steady growth. Samsung Bioepis, Celltrion Healthcare, Boryung Pharmaceutical, CJ HealthCare and Hanmi Pharmaceutical all announced in the first half of 2019 that they would begin or expan...
South Korean biopharmaceutical firm Celltrion announced Sept. 10 that its breast cancer biosimilar has been approved for sales in Canada.The regulatory body Health Canada has approved the data from nonclinical and clinical trials, and announced that Herzuma’s safety and effectiveness are compa...
South Korea’s Supreme Court has approved a grace period for Samsung BioLogics to defer the implementation of penalties imposed by the financial authorities by up to 30 days, the biopharma firm said in a regulatory filing on Sept. 10. As a result, sanctions on Samsung’s biopharma arm by K...
Celltrion Group expects to receive approval for biosimilar Remsima SC from European authorities for sales before the end of this year, founder and Chairman Seo Jung-jin said at a bio conference on Aug. 28. “On Aug. 20, we answered the European Medicines Agency’s questions related to Rems...
[Bio USA] Yposkesi’s 2nd plant to be in full swing in 2025: VP
[Bio USA] Who’s behind Samsung Biologics' evolving technology?
Hyundai chief vows to learn from past
SK hynix begins mass production of industry's highest-layer-count NAND chips
KB chief stresses role of finance in net-zero transition
Hyundai to produce Ioniq 5 with Indonesia’s batik design
[Bio USA] Samsung Biologics hints at sales push for new plant
LS Cable & System to build Korea's largest offshore wind farm
June 09, 2023
![[Bio USA] Yposkesi’s 2nd plant to be in full swing in 2025: VP](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2023/06/08/20230608000571_0.jpg)
![[Bio USA] Who’s behind Samsung Biologics' evolving technology?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2023/06/08/20230608000741_0.jpg)
![[Bio USA] Samsung Biologics hints at sales push for new plant](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2023/06/07/20230607000585_0.jpg&md=20230607180828)
